[PDE-5 inhibitor with improved pharmacokinetics. Far-reaching return to normality].
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002243:Carbolines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002986:Clinical Trials as Topic; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000201:enzymology*; D006207:Half-Life; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010727:Phosphoric Diester Hydrolases / Q000097:blood*; D012725:Sexual Behavior / Q000187:drug effects; D000068581:Tadalafil
D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human
PDE-5-Hemmer mit verbesserter Pharmakokinetik. Weit gehende Rückkehr zur Normalität.